[Polymyalgia rheumatica in 18-fluorodeoxyglucose-positron-emission-tomography/computed tomography : Improvement in diagnostic accuracy and differentiation from rheumatoid arthritis]
- PMID: 34851442
- PMCID: PMC9981502
- DOI: 10.1007/s00393-021-01133-w
[Polymyalgia rheumatica in 18-fluorodeoxyglucose-positron-emission-tomography/computed tomography : Improvement in diagnostic accuracy and differentiation from rheumatoid arthritis]
Abstract
Background: The diagnosis of patients with polymyalgia rheumatica (PMR) has relied upon the clinical examination of symptoms and laboratory parameters of inflammation until now. Currently, the use of different imaging modalities is being explored, including ultrasound, MRI and PET.
Objectives: The aim was to evaluate the diagnostic value of 18-fluorodeoxyglucose-positron-emission-tomography/computed tomography (18F-FDG-PET/CT) for PMR, in order to improve the sensitivity and specificity of diagnosing PMR and to improve the differential diagnosis of rheumatoid arthritis (RA).
Materials and methods: Examinations using 18F-FDG-PET/CT of 284 rheumatological patients, including 97 patients with PMR, were retrospectively evaluated over a 44-month period. Furthermore, 13 regions changed by inflammation were analysed via a three-dimensional region of interest (ROI) measurement with determination of maximum standardized uptake values (SUVmax), followed by statistical analyses.
Results and discussion: Patients with PMR presented significantly elevated uptake in all regions examined (p < 0.001), compared with a control group treated for rheumatological diseases. The method with the highest diagnostic relevance was represented by the combination of four SUVmax values of both anterolateral hip capsules and both ischial tuberosities, reaching a sensitivity of 91.3% and a specificity of 97.6% with a cut-off of 11.0 SUV at the initial diagnosis of PMR patients who had not yet received any immunosuppressive therapy. Patients with RA could be significantly distinguished from those with PMR at initial diagnosis in the same anatomical regions (p < 0.001).
Zusammenfassung: HINTERGRUND: Die Diagnose von Patienten mit Polymyalgia rheumatica (PMR) beruht bislang auf der klinischen Symptomatik und laborchemischen Entzündungsparametern. Aktuell wird der Nutzen verschiedener bildgebender Verfahren evaluiert, hierunter die Sonographie, MRT und PET.
Ziel der arbeit/fragestellung: Ziel war die Evaluation der diagnostischen Wertigkeit der 18-Fluordesoxyglukose-Positronenemissionstomographie/Computertomographie (18F-FDG-PET/CT) bei PMR, um die Sensitivität und Spezifität in der diagnostischen Aufarbeitung zu verbessern, sowie die rheumatoide Arthritis (RA) differentialdiagnostisch verbessert abzugrenzen.
Material und methoden: Es wurden 18F-FDG-PET/CT-Untersuchungen von 284 rheumatologischen Patienten – hierunter 97 Patienten mit PMR – aus einem 44-monatigen Zeitraum retrospektiv evaluiert. Weiter wurden 13 entzündlich veränderte Regionen via dreidimensionaler Region-of-interest(ROI)-Messung mit Bestimmung des maximalen Standardized-Uptake-Value (SUVmax) analysiert, gefolgt von statistischen Analysen.
Ergebnisse und diskussion: Patienten mit PMR zeigten im Vergleich mit einer rheumatologisch behandelten Kontrollgruppe signifikant erhöhte Anreicherungen in allen gemessenen Regionen (p < 0,001). Die Methode mit der stärksten diagnostischen Aussagekraft stellte die Kombination aus vier SUVmax-Messwerten – beider anterolateraler Hüftkapseln und beider Tubera ischiadica – dar, mit einer Sensitivität von 91,3 % und einer Spezifität von 97,6 % bei einem Cut-off von 11,0 SUV für die Erstdiagnose von PMR-Patienten, die noch keine immunsuppressive Therapie erhalten hatten. Patienten mit RA konnten bei Erstdiagnose an ebenjenen anatomischen Regionen signifikant von Patienten mit PMR unterschieden werden (p < 0,001).
Keywords: Diagnosis; Giant cell arteritis; Glucocorticoids; Inflammation; Rheumatoid arthritis.
© 2021. The Author(s).
Similar articles
-
Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography and computed tomography for differentiating polymyalgia rheumatica and rheumatoid arthritis: Using classification and regression tree analysis.Mod Rheumatol. 2024 Mar 28;34(3):474-478. doi: 10.1093/mr/road051. Mod Rheumatol. 2024. PMID: 37279960
-
Similarities and differences in fluorodeoxyglucose positron emission tomography/computed tomography findings in spondyloarthropathy, polymyalgia rheumatica and rheumatoid arthritis.Joint Bone Spine. 2013 Mar;80(2):171-7. doi: 10.1016/j.jbspin.2012.04.006. Epub 2012 Jun 29. Joint Bone Spine. 2013. PMID: 22749663
-
Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in polymyalgia rheumatica: an observational study.Clin Exp Rheumatol. 2023 Jul;41(7):1456-1462. doi: 10.55563/clinexprheumatol/kqyki5. Epub 2022 Dec 15. Clin Exp Rheumatol. 2023. PMID: 36533978
-
Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis.Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1876-1889. doi: 10.1007/s00259-020-05162-6. Epub 2020 Dec 28. Eur J Nucl Med Mol Imaging. 2021. PMID: 33372248 Free PMC article.
-
Clinical Value of FDG-PET/CT for the Evaluation of Rheumatic Diseases: Rheumatoid Arthritis, Polymyalgia Rheumatica, and Relapsing Polychondritis.Semin Nucl Med. 2017 Jul;47(4):408-424. doi: 10.1053/j.semnuclmed.2017.02.005. Epub 2017 Apr 11. Semin Nucl Med. 2017. PMID: 28583280 Review.
Cited by
-
Magnetic resonance imaging in polymyalgia rheumatica-contrast enhancement is not always needed.Z Rheumatol. 2024 May;83(4):269-276. doi: 10.1007/s00393-023-01394-7. Epub 2023 Aug 11. Z Rheumatol. 2024. PMID: 37566119 Free PMC article.
-
[Rheumatology centers according to the regulations of the Federal Joint Committee].Z Rheumatol. 2023 Sep;82(7):552-562. doi: 10.1007/s00393-022-01270-w. Epub 2022 Sep 28. Z Rheumatol. 2023. PMID: 36169704 German.
-
[Diagnosis of polymyalgia rheumatica: anamnesis and clinical aspects precede imaging].Z Rheumatol. 2023 Oct;82(8):706-707. doi: 10.1007/s00393-023-01413-7. Epub 2023 Sep 6. Z Rheumatol. 2023. PMID: 37673812 German. No abstract available.
References
-
- Ameer F, Mcneil J. Polymyalgia rheumatica: clinical update. Aust Fam Physician. 2014;43:373–376. - PubMed
-
- Camellino D, Paparo F, Morbelli SD et al (2021) Clinical and FDG-PET/CT correlates in patients with polymyalgia rheumatica. Clin Exp Rheumatol. Pubmed-ID PMID: 33822711 - PubMed
-
- Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European league against rheumatism/American college of rheumatology collaborative initiative. Ann Rheum Dis. 2012;71:484–492. doi: 10.1136/annrheumdis-2011-200329. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical